Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toluene SCHEMBL27555376 | 0.92 | LMNA (0.58) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL4861938 | 0.92 | LMNA (0.65) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL124611 | 0.92 | LMNA (0.65) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL1850918 | 0.92 | LMNA (0.65) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL5127452 | 0.89 | LMNA (0.61) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL28296329 | 0.85 | LMNA (0.50) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL7355317 | 0.85 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL2914390 | 0.85 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL48134 | 0.85 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 | |
| Toluene SCHEMBL27369787 | 0.85 | LMNA (0.73) | LMNATSHRALOX12ACHECES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1343212-A | Derivatives of monosaccharides as well adhesion inhibitors | RANBAXY LAB LTD (IN) | 2002-04-03 | — | — | CN | claimed |
| CN-103360444-B | The new technique for synthesizing of antiparasitic agent selamectin | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-11 | — | — | CN | disclosed |
| CN-103237800-B | Amide derivatives and use thereof | MITSUBISHI TANABE PHARMA CORP. (JP) | 2015-10-21 | — | — | CN | disclosed |
| CN-104271565-A | Amide pyridine derivatives and use thereof | MITSUBISHI TANABE PHARMA CORP | 2015-01-07 | — | — | CN | disclosed |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-09-10 | — | — | US | disclosed |
| CN-101412693-A | 4-[1-hydroxy-1-(2,3-dimethoxyphenyl)methyl]piperidine and method for preparing corresponding piperidine thereby | AVENTIS PHARMA INC (US) | 2009-04-22 | — | — | CN | disclosed |
| CN-101333184-A | Processes for the preparation of (r)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4 piperidinemethanol | AVENTIS PHARMA INC (US) | 2008-12-31 | — | — | CN | disclosed |
| CN-100436415-C | Process for the preparation of -alpha- (2, 3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl ] -4-piperidinemethanol | HOECHST PHARMACEUTICAL INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-7332607-B2 | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS HOLDINGS INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1736469-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol | Aventis Pharmaceuticals Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1734037-A2 | Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol\ | Aventis Pharmaceuticals Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | AVENTIS PHARMACEUTICALS INC. | 2004-10-21 | — | — | US | disclosed |
| US-6713627-B2 | FOR RECEPTOR ANTAGONISTS IN TREATMENT OF SCHIZOLPHRENIA, ANXIETY, VARIANT ANGINA, ANOREXIA VERVOSA, RAYNAUD'S PHENOMENON, INTERMITTENT CLAUDICATION, CORONARY OR PERIPHERAL VASOSPASMS, FIBROMYALGIA, CARDIAC ARRHYTHMIA'S, AND THROMBOSIS | AVENTIS PHARMACEUTICALS INC. | 2004-03-30 | — | — | US | disclosed |
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | AVENTISUB II INC. | 2002-10-17 | — | — | US | disclosed |
| EP-1192134-A2 | PROCESSES FOR THE PREPARATION OF (R)-G(A)-(2,3-DIMETHOXYPHENYL)-1-(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | Aventis Pharmaceuticals Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| CN-1300280-A | Process for the preparation of -alpha- (2, 3-dimethoxyphenyl) -1- [ 2- (4-fluorophenyl) ethyl ] -4-piperidinemethanol | HOECHST PHARMA (US) | 2001-06-20 | — | — | CN | disclosed |
| WO-1999046245-A2 | PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151717-A1 | Novel processes for the preparation or (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CBR1 | LMNA 1255/4885TSHR 2297/4885ALOX12 2045/4885 |
| US-20050261341-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | LMNA 1389/4885TSHR 2326/4885ALOX12 2379/4885 |
| US-20070265450-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | ADRM1, CYP2E1, OPRD1 | LMNA 1596/4885TSHR 2133/4885ALOX12 2574/4885 |
| US-20090227798-A1 | NOVEL PROCESSES FOR THE PREPARATION OF (R)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | CYP2E1, CYP1A1, ADRM1 | LMNA 1389/4885TSHR 2326/4885ALOX12 2379/4885 |
| US-20040210061-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol | CYP2E1, ADRM1, CYP1A1 | LMNA 1373/4885TSHR 2244/4885ALOX12 1904/4885 |
| US-20050010051-A1 | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | CYP2E1, CYP1A1, ADRM1 | LMNA 1389/4885TSHR 2326/4885ALOX12 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.